anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain an oil and fat having excellent digestibility and absorbability, having a short-chain fat at the 2-site of triglyceride and useful as a nutrient for oral or digestive tract administration or fat emulsion for intravenous injection, by carrying out ester interchange reaction using a 1,3-site specific lipase. CONSTITUTION:1mol of a triglyceride composed solely of short-chain fatty acid (e.g. synthetic medium-chain fatty acid triglyceride) or a cacao fat, palm fat, etc., containing relatively short fatty acid is added with 2-3mol of a fatty acid (e.g. linoleic acid, EPA, etc.) or a fatty acid ester or added with nearly equimolar amount of a triglyceride and subjected to ester interchange reaction with a lipase having 1,3-site specificity (e.g. LIPOZYME, product of Novo Co.). After the completion of the interchange reaction, the isolated fatty acid, fatty acid ester, glycerol, triglyceride, etc., are removed by conventional method to obtain the objective oil and fat wherein the 2-site fatty acid of triglyceride is 8-14C, preferably 8-12C fatty acid and the fatty acid of 1 and 3 site is &gt;=18C fatty acid.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medical report preparing system or the like, for more easily and speedily performing medical report preparation compared with the conventional manner.  &lt;P&gt;SOLUTION: Preparation of a detailed report schema is made possible speedily and easily by deforming a schema form registered in advance. In the case of using a single-layered form, a drag and drop operation or the like is made for the form while moving a cursor, for example, to a desired position, thereby deforming the form and preparing the report schema. In addition, in the case of using a multi-layered form having laminated graphics in which different colors or the like are assigned to layers, the respective layers are associated with characterizing portions of diagnostic regions, and the forms in the respective layers are deformed to to match the corresponding portions. In this manner, the forms are deformed, and the report schema is prepared.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
A clinical trial matching apparatus according to an embodiment includes processing circuitry. The processing circuitry receives patient information. The processing circuitry retrieves a clinical trial matching the patient from clinical trials based on the patient information, by referring to storage circuitry that stores data for associating a clinical trial in which medication conditions are set with the results of the clinical trial, for the clinical trials. The processing circuitry presents the retrieved clinical trial. The processing circuitry collects, and stores in the storage circuitry, the results obtained by conducting the retrieved clinical trial on the patient and patient&#39;s clinical information. The processing circuitry updates the conditions of the retrieved clinical trial based on the clinical information, when there is clinical information that can identify a significant difference in drug efficacy in the collected clinical information.
PURPOSE:To prepare a useful antiphlogistic and analgesic agent having suppressed side effects such as gastrointestinal disorder, without lowering the main effect of a non-steroid antiphlogistic and analgesic substance, by compounding a non-steroid antiphlogistic and analgesic substance and a 2,3-butanediol diester derivative as active components. CONSTITUTION:A non-steroid antiphlogistic and analgesic substance (e.g. indomethacin, aspirin, phenylbutazone, etc.) and a 2,3-butanediol diester derivative of formulaI(R1 and R2 are alkyl, alkenyl or group of formula II; R3 is H, alkyl, or cyano; R4 is phenyl, etc.) are used as active components, and mixed properly with a diluent such as starch, a binder such as sodium carboxymethylcellulose, etc. The amount of butanediol diester is preferably &gt;=0.1pt., especially 1-20pts. per 1pt. of the non-steroid antiphlogistic and analgesic substance.
Prostate Cancer (PCa) and androgen deprivation therapy (ADT) PCa is the most common cancer and the second leading cancer death in adult male globally. In Hong Kong, it is one of the most rapidly increasing cancer and is now the third most common cancer and the 4th leading cancer death in male. Despite the increased usage of serum PSA for early cancer diagnosis, more than 50% of patients were diagnosed at stage III \&amp;amp; IV, with lymph node +/- bone / visceral metastasis. Therefore, ADT is still commonly used in PCa patients, both as neo-adjuvant/ adjuvant to radiotherapy,as well as backbone therapy for metastatic disease.While the overall survival of PCa patients has been prolonged by ADT, there is also increasing concern about potential long-term side effects, in particular cardiovascular effect.

Therefore, there is a need for prospective studies to understand the role of close cardiovascular assessment, monitoring and treatment on the cardiovascular risk of PCa patients receiving ADT. Information on the risk factors at baseline; follow-up, and also treatment / secondary prevention adopted, will help to provide evidence to fill the current knowledge gap and build practical guidelines for clinical usage. In the long run, the data will also help to estimate the medical resources required for future health care planning to cope with the medical needs of the rapidly increasing PCa population.
The invention relates to cyber hospital system for providing doctors&#39; assistances from remote sites. A cyber hospital system is connected to a remote terminal through a network. The cyber hospital system includes an input unit, a first processor, and a transmitter. The input unit is configured to input patient condition information from the remote terminal through the network. The first processor is configured to collect first doctor information based on the patient condition information. The transmitter is configured to transmit the first doctor information to the remote terminal.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a series of compounds useful for the diagnosis of thrombosis and embolism of vein and artery, or a site of infectious disease, and a medicinal preparation containing them and capable of performing the diagnosis of these diseases easily and more accurately.  &lt;P&gt;SOLUTION: The use of an appropriate protecting group gives the synthetic analogues of lysine and glutamine, having reduced sensitivities against in vivo metabolism by peptidases, and achieves the following diagnostic objectives. The synthetic analogues of the lysine and glutamine give a function as a substrate of an enzyme, factor XIIIa for stabilizing fibrin even on being labeled with a detectable moiety. The use of appropriate protecting group especially gives the compounds having the reduced sensitivities against the in vivo metabolism by the peptidases, and therefore they become medicines useful for the diagnosis of thrombosis, embolism, arteriosclelosis, inflammation or cancer. These compounds are useful for the diagnosis of thrombosis, embolism, arteriosclelosis, inflammation or cancer.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
NEW MATERIAL:A fractionated water-soluble high polymer substance having &gt;=10,000 molecular weight, by extracting Didemnum varians with an aqueous solvent. USE:An antitumor agent having excellent antitumor action with extremely weak cytotoxicity and hardly any disorder in living bodies. PREPARATION:Didemnum varians which is a species of marine organism colony ascidian is extracted with water or an aqueous solution containing a water-soluble inorganic salt, such as sodium chloride, dissolved in water, etc., by a conventional method. The extract solution is collected by centrifugal separation, etc., and subjected to molecular weight fractionation by a method for dialysis, molecular sieve, etc., to afford the aimed substance having &gt;=10,000 molecular weight. Freeze-drying, etc., of necessary, is carried out. A formulation is then prepared from the resultant fractionated substance by a conventional method to provide an antitumor agent. The dose thereof is 5-2,000mg/kg, preferably 10-500mg/kg per day in the case of an injection.
The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn&#39;s disease and ulcerative colitis. Therapeutic compositions of the invention include compositions that can neutralize hydrogen peroxide, such as reducing agents and oxidizing agents. In one embodiment, a composition includes dihydrolipoic acid as a first reducing agent, an aminosalicylic acid, and a mast cell stabilizer. In another embodiment, the composition further includes a second reducing agent. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient.
PURPOSE:To provide an adenosine deaminase inhibitor containing an adenosine derivative as the active component. CONSTITUTION:A compound of the formula (R1, R2 and R3 are each H or an alkyl; R is H, an alkyl, an alkenyl, an alkynyl, an alkoxy, phenyl, OH, amino, a halogen, etc.; X is H, an alkyl, a cycloalkyl, etc.), e.g. 2&#39;-O-methyladenosine is contained as the active component. This inhibitor is useful for prevention and therapy of ischemic heart disease, diseases caused by cerebrovascular disorder, kidney diseases, inframmatory allergic diseases, etc. In addition, this inhibitor can inactivate active oxygen generated at an ischemic part in recirculation of blood after an operation and is, therefore, useful for prevention and therapy of postoperative complicated diseases. The dosage is 0.1 to 5000mg, preferably 0.2 to 3000mg/day per an adult in the case of oral administration. One third or tenth the dosage in the case of oral administration is administrated in the case of parenteral administration such as injection.
FIELD: veterinary virology. SUBSTANCE: vaccine consists of two antigenously different strains named &#34;Zakarpatsky&#34; and &#34;Navlya-96&#34; circulating in Russia and in the nearest abroad. Moreover, this vaccine contains theotropine at final concentration 0.06-0.08% which efficiently inactivates the virus by not affecting its immunogenic properties. To decrease the viscosity of vaccine its composition is supplemented with a vaccine emulsifier 139 at final concentration being 0.5-4%. The vaccine is very convenient in application being stable at storage, it enables to obtain 100% protection of vaccinated swines for the whole raising cycle. EFFECT: higher efficiency. 2 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a physiologically active composition which arranges the reinforcement of self immunological functions and homeostasis balance to maintain health and has such action to make physical conditions hardly suffering from diseases.  &lt;P&gt;SOLUTION: This physiologically active composition comprises a plant extract obtained by steaming a plant at 120 to 250°C and then extracting the steamed plant with a solvent. This physiologically active composition, wherein the plant is a gramineous plant. A method for producing a physiologically active composition comprises steaming a plant at 120 to 250°C and then extracting the steamed plant with a solvent. The method for producing the physiologically active composition, wherein the plant is a gramineous plant.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To eliminate duplication and emission of various workings by sorting the contents of a prescription by a sorting means into first file information to be processed with a preparator and second file information to be processed otherwise to output. CONSTITUTION:A fully automatic drug packing machine 1 as one example of preparators is made up of a drug housing/withdrawing device 2 and a packer 24 and the drug housing/withdrawing device 2, is provided with a plurality of vertical type withdrawing bodies 3... in a box body 2&#39;. Multiple stages of racks 6 set one upon another are arranged in each withdrawing body 3 and are each provided with a plurality of tablet feeders 8. The tablet feeders 8 have a housing section to house multiple tablets of one type and a discharging section to discharge the tablets in the housing section one at a time. The packing machine 1 is controlled through an operating unit comprising a microcomputer. Here, the contents of a prescription are sorted into first file information to be processed with the packing machine 1 and second file information to be processed otherwise to control.
Embodiments of the present invention provide a method and system for dynamically controlling an appliance based on information received from a wearable device, to regulate the user&#39;s health. A wearable device is identified and configured to monitor at least one physiological aspect of the user. A controllable appliance with at least one sensor and at least one controllable setting is also identified. Health information of the user is received and utilized in generating, a user profile which comprises parameters related to the health of the user. Data from the wearable device and data from the controllable appliance is analyzed and it is determined whether the data matches the parameters related to the health of the user. If the data does not match the parameters related to the health of the user, then at least one controllable setting of the at least one controllable appliance is adjusted.
PURPOSE:To enable effective treatment of malignant tumor, etc., by administering fragmented protein A produced by the enzymatic treatment of protein A originated from Staphylococcus aureus Cowan I strain. CONSTITUTION:Protein A originated from Staphylococcus aureus Cowan I strain is subjected to enzymatic treatment (e.g. with trypsin) and the obtained fragmented protein A is administered for treatment of malignant tumor, etc. The fragmented protein A is composed of 5 kinds of polypeptides A, B, C, D and E. Since the above polypeptides have relatively low molecular weight (i.e. &lt;=10,000), it can be administered to blood causing little allergic reaction which is supposed to be caused by administration of protein originated from microbial cell. The necrosis, fibrillation or contraction of the tumor tissue of malignant tumor was found by administration of the fragmented protein.
Pregnancy is a period of significant emotional and physical changes, with up to 30% of expecting mothers experiencing high stress. After birth, around 15-20% of new mothers suffer from postpartum depression, and 25-35% experience anxiety. Despite broad availability of mobile apps aimed at these challenges, none of them have been rigorously tested through clinical studies. To fill this gap, we developed Powerly, a science-based mobile app designed to help prevent postpartum depression and anxiety.

In this study, 140 healthy pregnant women will be randomly assigned to one of two groups: one will use the Powerly app for four weeks, while the other will receive care as usual (CAU). Powerly is grounded in cognitive behavioral therapy (CBT) and personalized to the individual's needs, with input from healthcare professionals and pregnant women. We will collect information on participants\&#39; mental health at three points: before they start using the app, after four weeks of app use / CAU, and six weeks after giving birth. The app's effectiveness will be evaluated by examining improvements in mental health outcomes, such as reduced rates of postpartum depression and anxiety, better emotion regulation, and stronger maternal bonding with a baby.
The present invention discloses one kind of over-the-counter medicine, named as Yangrongtongbining, for treating tetanic rachitis and other diseases. It is prepared with 28 kinds of Chinese medicinal materials, including ginseng, wolfberry fruit, angelica, etc. and is prepared into capsule, tablet or bolus. It has the functions of invigorating vital energy and blood, strengthening body&#39;s resistance, relaxing muscles and joints, stopping pain, etc. and may be used to cure tetanic rachitis radically. It has also high curative effect on rheumarthritis, rheumatoid arthritis, pain waist and legs, etc.
A controlled release dosage form for sertraline has a core comprising a sertraline-containing composition and a water-swellable composition wherein the water-swellable composition is in a separate region within the core. A coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough. In one embodiment, the dosage form releases sertraline to the use environment at an average rate of 6 to 10 wt. % per hour from the second to the twentieth hour after introduction to a use environment and less than about 25 wt.% for the first two hours and at least 70 wt.% by the twelfth hour, where the percentages correspond to the mass of drug released from the tablet divided by the total mass of drug originally present in the tablet. In another embodiment, the dosage form releases less than about 25 wt.% of sertraline to the use environment by the second hour after introduction of the dosage form to the use environment, and delivers at least 25 wt.% from the eighth to the twenty-fourth hour. &lt;IMG&gt;
Athletic activity may be tracked while providing encouragement to perform athletic activity. For example, energy expenditure values and energy expenditure intensity values may be calculated and associated with a duration and type of activity performed by an individual. These values and other movement data may be displayed on an interface in a manner to motivate the individual and maintain the individual&#39;s interest. The interface may track one or more discrete &#34;sessions&#34;. The sessions may be associated with energy expenditure values during a duration that is within a second duration, such as a day, that is also tracked with respect to variables, such as energy expenditure. Other individuals (e.g., friends) may also be displayed on an interface through which a user&#39;s progress is tracked. This may allow the user to also view the other individuals&#39; progress toward completing an activity goal and/or challenge.
The invention relates to nanoparticles for the administration of biologically active molecules comprising a biodegradable polymer, preferably the copolymer of methyl vinyl ether and maleic anhydride (MVE/MA), and thiamine. Such nanoparticles are simply produced having excellent characteristics of bioadhesion, size and zeta potential, rendering them suitable for the administration of active molecules. The procedure of obtainment of such nanoparticles is realised by simple incubation for a short period of time, the nanoparticles being preformed in an aqueous medium. The biologically active molecule may be incorporated during the process of formation of the nanoparticles by desolvation or through modification with thiamine. By oral route said nanoparticles develop bioadhesive interactions with the gastrointestinal mucous membrane, including the lymphoid tissue associated with mucous membranes (Peyer&#39;s patches), and are therefore useful for increasing the oral bioavailability of various drugs or inducing immune responses in mucous membranes. Thus when such nanoparticles contain an antigen within the matrix thereof the resultant mixture is capable of inducing strong immune responses to the encapsulated antigen. Such stimulating effect on immune response is useful in vaccination and immunotherapy.
It is an object of the invention to improve a user&#39;s breathing for a specific application (e.g. diagnostic imaging, falling asleep improvement (shortening sleep onset), delivery, tinnitus control therapy, CORD, blood pressure control). This object is achieved by a breathing adaptation system configured for influencing a breathing parameter of a user&#39;s breathing pattern in order to meet a goal of decreasing or increasing the influenced breathing parameter to a certain extent in a user specific manner. The breathing adaptation system comprises a sensor, configured for monitoring a current value of the influenced breathing parameter of the user. The breathing adaptation system further comprises a feedback unit configured for providing feedback to the user about a preferred value of the influenced breathing parameter, wherein the preferred value is different from the current value of the influenced breathing parameter ( 310 ). The breathing adaptation system further comprises a control unit, comprising program code means for determining the preferred value of the influenced breathing parameter in a user specific manner by means of an intelligent agent, wherein the control unit is implemented such that the intelligent agent is rewarded ( 330 ) by means of a reward function after performing the determination of the preferred value ( 320 ) of the influenced breathing parameter, wherein the reward function is such that it balances the reward for obtaining the goal and the ability of the user to breathe according to a breathing pattern having the preferred value for the influenced breathing parameter.
PURPOSE:To obtain a preparation having good absorptivity of chlorophyll having bactericidal action, etc., into interior of the body and excellent chlorophyll effect by cooperative action with protein by kneading a product obtained by ultrasonic treatment of a chlorophyll-containing substance in ethanol solution and a protein-containing substance. CONSTITUTION:Chloroplast plant, green alga or dung of silk worm, etc., is used as raw material of chlorophyll and said raw material is dipped in aqueous solution of ethanol, preferably concentrated aqueous solution of &gt;=80%, then ultrasonic wave is irradiated to said dipped solution and simultaneously stirred with stirring wing. Timing of ultrasonic wave irradiation is about 60-200min. Resultant chlorophyll-extracted ethanol solution is filtered and residue of raw material is removed, then collected. Next, a protein-containing substance such as protein G, preferably &gt;=50% protein-containing is added to said chlorophyll- extracted ethanol solution, kneaded and formed as granular, etc., using dryer, etc. Mixing ratio of chlorophyll solution and protein-containing substance is 1:1, preferably 3:1.